PRPH (STOCKS)
PROPHASE LABS INC
$0.085000
+0.005000 (+6.25%)
Prev close: $0.080000
Company Information
- Exchange
- OTC Link
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Other
- CEO
- Ted William Karkus
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3.93M
- Employees
- 96
- P/E (TTM)
- -0.60
- P/B (TTM)
- 0.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2025 (Q2)
|
$-1.10 | $-1.53 | +0.4300 | +28.10% |
|
Mar 2025 (Q1)
|
$-1.40 | $-1.84 | +0.4360 | +23.75% |
|
Mar 2024 (Q4)
|
$-15.90 | $-2.45 | -13.4520 | -549.51% |
|
Sep 2024 (Q3)
|
$-3.50 | $0.41 | -3.9080 | -957.84% |
Financial Statements
| Revenues | $4.35M |
| Benefits Costs and Expenses | $27.73M |
| Cost Of Revenue | $2.96M |
| Costs And Expenses | $27.73M |
| Gross Profit | $1.38M |
| Operating Expenses | $19.43M |
| Depreciation and Amortization | $2.25M |
| Research and Development | $107.00K |
| Other Operating Expenses | $17.07M |
| Operating Income/Loss | -$18.05M |
| Income/Loss Before Equity Method Investments | -$23.22M |
| Income/Loss From Continuing Operations After Tax | -$23.39M |
| Income/Loss From Continuing Operations Before Tax | -$23.39M |
| Income/Loss From Discontinued Operations Net Of Tax | $8.64M |
| Income/Loss From Discontinued Operations Net Of Tax During Phase Out | -$102.00K |
| Income/Loss From Discontinued Operations Net Of Tax Gain/Loss On Disposal | $8.75M |
| Income/Loss From Equity Method Investments | -$166.00K |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$14.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$14.74M |
| Net Income/Loss Available To Common Stockholders, Basic | -$14.74M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.74 |
| Diluted Earnings Per Share | -$1.74 |
| Basic Average Shares | 8,489,000 |
| Diluted Average Shares | 8,489,000 |
| Assets | $59.87M |
| Current Assets | $3.15M |
| Inventory | $70.00K |
| Other Current Assets | $3.08M |
| Noncurrent Assets | $56.72M |
| Intangible Assets | $7.17M |
| Non-current Prepaid Expenses | $61.00K |
| Other Non-current Assets | $49.49M |
| Liabilities | $56.36M |
| Current Liabilities | $53.08M |
| Wages | $530.00K |
| Other Current Liabilities | $52.55M |
| Noncurrent Liabilities | $3.28M |
| Equity | $3.51M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.51M |
| Liabilities And Equity | $59.87M |
| Net Cash Flow From Operating Activities | -$8.34M |
| Net Cash Flow From Operating Activities, Continuing | -$8.94M |
| Net Cash Flow From Operating Activities, Discontinued | $597.00K |
| Net Cash Flow From Investing Activities | $920.00K |
| Net Cash Flow From Investing Activities, Continuing | $120.00K |
| Net Cash Flow From Investing Activities, Discontinued | $800.00K |
| Net Cash Flow From Financing Activities | $6.84M |
| Net Cash Flow From Financing Activities, Continuing | $6.87M |
| Net Cash Flow From Financing Activities, Discontinued | -$35.00K |
| Net Cash Flow | -$588.00K |
| Net Cash Flow, Continuing | -$1.95M |
| Net Cash Flow, Discontinued | $1.36M |
| Comprehensive Income/Loss | -$14.74M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$14.74M |
| Other Comprehensive Income/Loss | -$14.74M |